iloprost and Cardiomyopathies

iloprost has been researched along with Cardiomyopathies* in 5 studies

Reviews

1 review(s) available for iloprost and Cardiomyopathies

ArticleYear
Free radical scavengers in myocardial ischemia.
    Federation proceedings, 1987, May-15, Volume: 46, Issue:7

    Reperfusion of ischemic myocardium is recognized as potentially beneficial because mortality is directly related to infarct size, and the latter is related to the severity and duration of ischemia. However, reperfusion is associated with extension of the injury that is additive to that produced by ischemia alone. The phenomenon of reperfusion injury is caused in large part by oxygen-derived free radicals from both extracellular and intracellular sources. The loci of oxygen-free radical formation include: myocardial sources (mitochondria), vascular endothelial sources (xanthine oxidase and other oxidases), or the inflammatory cellular infiltrate (neutrophils). Experimental studies have shown that free radical scavengers and agents that prevent free radical production can reduce myocardial infarct size in dogs subjected to temporary regional ischemia followed by reperfusion. Superoxide dismutase and catalase, which catalyze the breakdown of superoxide anion and hydrogen peroxide, respectively, limit experimental myocardial infarct size. The free radical scavenging agent N-(2-mercaptopropionyl)glycine (MPG) is reported to be effective in limiting infarct size. The ischemic-reperfused myocardium derives significant protection when experimental animals are pretreated with the xanthine oxidase inhibitor allopurinol. Neutrophils also serve as a significant source of oxygen-derived free radicals at the site of tissue injury. A number of agents have been shown to directly inhibit neutrophil-derived oxygen free radical formation and neutrophil accumulation within the reperfused myocardium. These agents include ibuprofen, nafazatrom, BW755C, prostacyclin, and iloprost. Thus, free radical scavengers and agents that prevent free radical formation can provide significant protection to the ischemic-reperfused myocardium.

    Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Allopurinol; Cardiomyopathies; Catalase; Coronary Circulation; Epoprostenol; Free Radicals; Ibuprofen; Iloprost; Neutrophils; Oxygen; Pyrazoles; Pyrazolones; Superoxide Dismutase; Tiopronin

1987

Other Studies

4 other study(ies) available for iloprost and Cardiomyopathies

ArticleYear
Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.
    European heart journal, 2006, Volume: 27, Issue:10

    The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX.. Lewis Lung Carcinoma cells were implanted subcutaneously in the flank of C57BL/6 mice. DOX treatment was commenced from when tumours became visible. Iloprost was administered from prior to DOX treatment until sacrifice. Echocardiography and invasive haemodynamic measurements were performed immediately before sacrifice. As expected, DOX induced cardiac cell apoptosis and cardiac dysfunction, both of which were attenuated by iloprost. Also, iloprost alone had no effect on tumor growth and indeed, did not alter the DOX-induced suppression of this growth.. In a murine model, iloprost attenuated the acute cardiac injury and dysfunction induced by DOX therapy without compromising its chemotherapeutic effect.

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Lewis Lung; Cardiomyopathies; Cell Division; Doxorubicin; Drug Interactions; Iloprost; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Neoplasm Transplantation; Tumor Cells, Cultured

2006
Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumor suppression.
    European heart journal, 2006, Volume: 27, Issue:21

    Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cell Death; Doxorubicin; Drug Interactions; Iloprost; Mice; Vasodilator Agents

2006
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.
    The Journal of clinical investigation, 2001, Volume: 108, Issue:4

    The clinical use of doxorubicin, an anthracycline chemotherapeutic agent, is limited by cardiotoxicity, particularly when combined with herceptin, an antibody that blocks the HER2 receptor. Doxorubicin induces cyclooxygenase-2 (COX-2) activity in rat neonatal cardiomyocytes. This expression of COX-2 limits doxorubicin-induced cardiac cell injury, raising the possibility that the administration of a prostaglandin may protect the heart during the in vivo administration of doxorubicin. Doxorubicin (15 mg/kg) administered to adult male Sprague Dawley rats induced COX-2 expression and activity in cardiac tissue. Prostacyclin generation measured as the excretion of 2,3-dinor-6-keto-PGF(1alpha) also increased, and this was blocked by a COX-2 inhibitor, SC236. In contrast, administration of a COX-1 inhibitor SC560 at a dose that reduced serum thromboxane B2 by more than 80% did not prevent the doxorubicin-induced increase in prostacyclin generation. Doxorubicin increased cardiac injury, detected as a rise in plasma cardiac troponin T, serum lactate dehydrogenase, and cardiomyocyte apoptosis; this was aggravated by coadministration of SC236 but not SC560. The degree of injury in animals treated with a combination of doxorubicin and SC236 was attenuated by prior administration of the prostacyclin analogue iloprost. These data raise the possibility of protecting the heart during the administration of doxorubicin by prior administration of prostacyclin.

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonic Acid; Aspirin; Biomarkers; Cardiomyopathies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Doxorubicin; Enzyme Induction; Epoprostenol; Heart; Iloprost; Isoenzymes; L-Lactate Dehydrogenase; Male; Membrane Proteins; Myocardium; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Thromboxane B2; Transcription Factors; Troponin T

2001
Haemolytic uraemic syndrome, cardiomyopathy, cutaneous vasculopathy and anti-phospholipid activity.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:11

    Topics: Acute Kidney Injury; Antiphospholipid Syndrome; Cardiomyopathies; Child; Hemolytic-Uremic Syndrome; Humans; Iloprost; Male; Peripheral Vascular Diseases; Peritoneal Dialysis, Continuous Ambulatory; Plasmapheresis; Skin

2000